Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Amazon AMZN has rallied 48.9% in the past year on the back of exceptional business execution and groundbreaking AI ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $456 and keeps an Equal Weight rating on the ...

Blink Ops, the AI security automation platform, today announced record growth marked by 400% increase in year-over-year ...

Notably, Vertex Pharmaceuticals (NASDAQ: VRTX), which focuses on developing treatments for rare diseases, has significantly outpaced both its biotechnology peers and the S&P 500 since early 2022.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Google might have just invested another billion dollars into Anthropic, who is one of the main rivals of OpenAI.

Haivision Systems Inc. ("Haivision" or the "Company") , a leading global provider of mission critical, real-time video networking and visual collaboration solutions, today announced that it has ...

Black Hills Group of the South Dakota Sierra Club program, 6 p.m., Outdoor Campus West, Rapid City. Free. Speaker will be Seth Tupper, editor in chief of South Dakota Searchlight. Tupper will speak ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...